QUICKNOTE: H1 Results in Line, R&D Pipeline Expands
3SBio, China's leading biotech company, posted H1 results in line with pre-deal expectations. The recent acquisition of Zhejiang Wansheng broadens...
349 Views
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
489 Views
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
559 Views
Unique biopharmaceutical company with high barrier of entry, high growth expected, take the deal
3SBio is a leading biopharmaceutical company based in China offering products including EPIAO to cure anemia in Chronic Kidney Disease (CKD),...
364 Views
A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal
3SBio, a leading Chinese biotechnology company, plans to re-list in Hong Kong after de-listing from NASDAQ in 2013. The company's two main...
399 Views